The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2016

Filed:

Sep. 28, 2011
Applicants:

James M Wilson, Glen Mills, PA (US);

Anna P Tretiakova, Philadelphia, PA (US);

Jenny Agnes Greig, Philadelphia, PA (US);

Inventors:

James M Wilson, Glen Mills, PA (US);

Anna P Tretiakova, Philadelphia, PA (US);

Jenny Agnes Greig, Philadelphia, PA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2006.01); C12N 15/86 (2006.01); C12N 7/00 (2006.01); C12N 9/22 (2006.01); A61K 48/00 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); C12N 7/00 (2013.01); A61K 48/0066 (2013.01); C07K 14/4702 (2013.01); C07K 2319/09 (2013.01); C07K 2319/715 (2013.01); C07K 2319/80 (2013.01); C07K 2319/81 (2013.01); C07K 2319/92 (2013.01); C12N 9/22 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14151 (2013.01); C12N 2800/30 (2013.01); C12N 2800/40 (2013.01); C12N 2800/80 (2013.01); C12N 2830/002 (2013.01); C12N 2830/003 (2013.01); C12N 2830/005 (2013.01); C12N 2830/006 (2013.01); C12N 2830/20 (2013.01); C12N 2840/203 (2013.01);
Abstract

The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as 'PITA' (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.


Find Patent Forward Citations

Loading…